Hepion Pharmaceuticals Inc (HEPA)

[crudeoil24]

Also, have FDA phase III trials >> EDISON, N.J., Aug. 3, 2015 /PRNewswire/ — ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company’s pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). The first patient in the study enrolled at Center for Clinical Studies in Houston, Texas. The study will build upon prior clinical results for FV-100, including Phase 1 trials and a large Phase 2 clinical trial in shingles patients, which demonstrated favorable safety and tolerability for FV-100.



James Sapirstein, CEO of ContraVir, commented, “We are pleased to enroll the first patient in the Phase 3 study and to move forward in our efforts to develop treatment options for patients with shingles and acute shingles-associated pain. The enrollment is an important milestone for ContraVir as we advance our current pipeline as this brings us one step closer to commercialization.”